Surgery · Medical Literature
The UroLume endoprosthesis and UroLume cripple syndrome: a systematic review and meta-analysis of pathophysiology, complications, surgical management, psychological burden, and epidemiology of surviving patients worldwide.
Abstract
The UroLume endoprosthesis (AMS/Endo-care), commercially available 1988-2007 and FDA-approved in 1996, was positioned as a permanent minimally invasive solution for recurrent bulbar urethral stricture and benign prostatic hyperplasia. Despite early procedural success, long-term data revealed a severe complication profile-including irreversible urethral destruction, spongiofibrosis, MDR infections, chronic kidney disease, and significant psychological morbidity-culminating in a clinical entity described here under an author-proposed conceptual framework termed 'UroLume Cripple Syndrome'. To synthesise four decades of evidence on UroLume pathophysiology, complications, surgical management hierarchy, psychological burden, and cumulative multimorbidity; to perform a pooled meta-analysis of primary complication endpoints; and to present an original epidemiological model estimating surviving patients globally and in Greece in 2026. PRISMA 2020-compliant systematic review and meta-analysis. Databases searched: PubMed, Embase, Cochrane Library (inception to March 2026). peer-reviewed studies of UroLume implantation, explantation, or post-UroLume reconstruction; minimum 12-month follow-up; series n ≥ 10. Study quality assessed using the Newcastle-Ottawa Scale (NOS). Random-effects meta-analysis (DerSimonian-Laird estimator) performed for three primary complication endpoints across all 43 included studies. PROSPERO registration submitted; number pending. Forty-three studies met inclusion criteria (n = 3847 patients). Pooled meta-analysis (n = 2730 in quantitative pool): restenosis/tissue ingrowth 37.9% (95% CI 36.1-39.8%, I2 = 0%); stent explantation 8.7% (95% CI 7.7-9.8%, I2 = 0%); urinary incontinence 9.7% (95% CI 8.7-10.9%, I2 = 0%). Complete epithelialisation, irreversible after 12 months, affects approximately 8-13% of long-term survivors. A six-filter epidemiological model provides a hypothesis-generating estimate of fewer than 100 clinically active patients globally exhibiting this severe profile. The proposed framework of UroLume Cripple Syndrome conceptualizes a complex iatrogenic condition with distinct pathophysiological, reconstructive, and psychological dimensions. Specialized published institutional pathways remain confined to fewer than 10 centers worldwide, highlighting the need for structured registry creation and guideline consensus to support this legacy cohort.
Clinical relevance
What is the pooled prevalence of major complications (restenosis/tissue ingrowth, stent explantation, urinary incontinence) following UroLume endoprosthesis implantation across four decades of published literature, and how many patients are estimated to be surviving globally with a UroLume in situ in 2026? __SNAPSHOT__ {"studyDesign":"PRISMA 2020-compliant systematic review with random-effects meta-analysis; supplemented by an original author-constructed epidemiological model","setting":"Multinational; databases searched: PubMed, Embase, Cochrane Library (inception to March 2026). Implantation era: 1988–2007 across multiple countries. No single institution type.","sampleSize":"n=3,847 patients across 43 included studies","population":"Males who underwent UroLume endoprosthesis implantation, explantation, or post-UroLume urethral reconstruction for recurrent bulbar urethral stricture or benign prostatic hyperplasia; minimum 12-month follow-up required for inclusion","intervention":"UroLume urethral endoprosthesis (AMS/Endo-care); a permanent self-expanding woven metallic stent commercially available 1988–2007 and FDA-approved 1996","comparator":"Not applicable; single-arm aggregate analysis — no active comparator reported","primaryOutcome":"Pooled complication rates: (1) restenosis or tissue ingrowth; (2) stent explantation; (3) urinary incontinence. Secondary characterization includes complete epithelialisation rate, post-UroLume urethroplasty success, psychological burden, and an epidemiological estimate of surviving patients in 2026.","followUp":"Minimum 12 months per inclusion criteria; upper range of individual study follow-up not reported in available abstract","fundingSource":"Not reported"}
Key findings
Across 43 studies (n=3,847 patients), the random-effects meta-analysis yielded the following pooled complication rates: restenosis or tissue ingrowth 37.9% (95% CI 36.1%–39.8%; I²=0%); stent explantation 8.7% (95% CI 7.7%–9.8%; I²=0%); and urinary incontinence 9.7% (95% CI 8.7%–10.9%; I²=0%). Heterogeneity was low for all three primary endpoints (I²=0%), suggesting a consistent signal across included studies. Complete epithelialisation — described as irreversible beyond 12 months post-implantation and designated as the defining endpoint of 'UroLume Cripple Syndrome' — was estimated to affect approximately 8–13% of long-term survivors (specific confidence intervals not reported in the abstract). Post-UroLume buccal mucosa graft (BMG) urethroplasty achieved a disease-free survival rate of 76.7% at 5 years when explantation was feasible (CI and p-value not reported in abstract). Additional adverse events qualitatively described but not pooled with effect estimates include irreversible urethral destruction, spongiofibrosis, multidrug-resistant (MDR) infections, chronic kidney disease, and severe psychological morbidity. A novel bottom-up sequential epidemiological model — incorporating WHO 2021 actuarial tables, published explantation rates, multimorbidity-adjusted excess mortality, age distributions, complete epithelialisation prevalence, and reconstruction failure rates — estimated 2,500–5,000 patients globally with a UroLume in situ in 2026, declining to fewer than 100 clinically active patients aged <60 years after full multimorbidity adjustment. A six-filter sequential model specific to Greece converged to an estimated 1 surviving patient aged <60 years with complete epithelialisation following failed reconstruction. NNT and NNH were not calculable from available data; no p-values for the pooled effect estimates were reported in the abstract.
Practice implications
This systematic review and meta-analysis establishes that the UroLume endoprosthesis carries a substantial long-term complication burden: approximately 38 in 100 implanted patients will develop clinically significant restenosis or tissue ingrowth, nearly 1 in 10 will require surgical explantation, and nearly 1 in 10 will develop urinary incontinence. The remarkably low I² (0%) across all primary endpoints lends internal consistency to these estimates, although it may also reflect homogeneity in study populations rather than true global representativeness. The concept of 'UroLume Cripple Syndrome' is an author-proposed conceptual framework and clinical entity, not a pre-existing consensus-defined diagnosis; clinicians should interpret this terminology accordingly. The study does NOT establish causality for individual complications beyond what is attributable to the device itself (confounding by indication is likely, as the device was used in patients with complex, refractory stricture disease), does not provide comparative risk against alternative interventions (e.g., urethroplasty), and does not characterize the full spectrum of patients who may have tolerated the device without long-term sequelae (survivorship and publication bias are significant concerns). The 5-year BMG urethroplasty success rate of 76.7% is clinically relevant for reconstruction planning but is derived from included study populations with variable definitions of 'success,' and case selection strongly influences outcomes. The epidemiological model estimating global survivor burden, while methodologically transparent (WHO actuarial data, sequential filtering), represents a modelling exercise and is subject to substantial uncertainty given incomplete global implantation records. Given that this work was initially posted as a preprint (medRxiv, April 2026) and only recently attributed to a peer-reviewed PMID, full peer-reviewed scrutiny of the methods, GRADE evidence profiling, and risk-of-bias assessments is not accessible from the abstract alone — this is a critical interpretive limitation. Findings are applicable to any clinician who may encounter a patient with a historical UroLume implant; they do not apply to currently marketed urethral devices. Patients inadequately represented include women, those with non-bulbar stricture locations, and patients from low-income or non-English-language healthcare settings. __LIMITATIONS__ Single-arm design with no comparator group — relative risk versus alternative treatments (urethroplasty, urethrotomy, suprapubic catheter) cannot be determined,Pooled data span approximately 35 years (1988–2026), incorporating studies with heterogeneous follow-up durations, outcome definitions, and patient selection criteria — even with I²=0%, clinical heterogeneity across eras is substantial,Significant risk of publication and survivorship bias: patients with catastrophic outcomes or early mortality are likely underrepresented; series with favorable outcomes may be more frequently published,Risk-of-bias assessment methodology for individual included studies is not detailed in the abstract; most underlying studies are retrospective cohorts or case series (low-quality evidence hierarchy),The 'UroLume Cripple Syndrome' designation is an author-proposed conceptual construct, not a validated consensus clinical entity, which limits nosological applicability and may introduce framing bias,The epidemiological survivor model is a theoretical bottom-up construct dependent on assumptions derived from published explantation rates and actuarial tables — actual surviving patient numbers globally are unknown, and the estimate of 1 patient in Greece is highly speculative,Complete epithelialisation prevalence (8–13%) is reported as a range without CIs or pooled effect estimates, limiting precision,BMG urethroplasty success rate of 76.7% at 5 years is drawn from pooled reconstructive series with variable patient selection, technique heterogeneity, and success definitions,Funding source is not reported — potential conflicts of interest cannot be assessed,Peer-reviewed full-text version was not independently accessible at time of summary preparation; findings are based solely on abstract and preprint-derived data __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ Among patients who received a UroLume urethral endoprosthesis (now off-market since 2007), this meta-analysis of 43 studies and nearly 3,900 patients estimates pooled rates of restenosis/tissue ingrowth of 37.9%, stent explantation of 8.7%, and urinary incontinence of 9.7% — all with low heterogeneity. When explantation is feasible, buccal mucosa graft urethroplasty offers an approximately 77% disease-free 5-year reconstruction rate. Clinicians encountering patients with historical UroLume implants should maintain a high index of suspicion for multisystem iatrogenic morbidity, pursue early urological specialist referral, and be aware that a minority of long-term survivors may harbor irreversible urethral destruction for which reconstructive options remain limited.